Universität zu Köln

Journal Article

Alidousty, C., Baar, T., Martelotto, L. G., Heydt, C., Wagener, S., Fassunke, J., Duerbaum, N., Scheel, A., Frank, S., Holz, B., Binot, E., Kron, A., Merkelbach-Bruse, S., Ihle, M., Wolf, J., Buettner, R. and Schultheis, A. M. (2018). Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC; a central role of TP53 mutations. Virchows Arch., 473. S. S315 - 1. NEW YORK: SPRINGER. ISSN 1432-2307

Brandes, V, Scheffler, M., Kambartel, K., Ortiz-Cuaran, S., Scheel, A., Michels, S., Nogova, L., Fischer, R., Abdulla, D., Merkelbach-Bruse, S., Buettner, R., Sos, M. L. and Wolf, J. (2016). Targeting HER2-and MET co-amplification in patients with EGFR mutation resistant to EGFR-TKI therapy. Oncol. Res. Treat., 39. S. 172 - 173. BASEL: KARGER. ISSN 2296-5262

Eisert, A., Scheffier, M., Gogl, L., Frank, R., Scheel, A., Merkelbach-Bruse, S., Michels, S., Fischer, R., Buettner, R. and Wolf, J. (2015). Clinical and genetic presentation of high-level cMET-amplified Non-small cell lung cancer (NSCLC) with adenocarcinoma histology. Oncol. Res. Treat., 38. S. 16 - 17. BASEL: KARGER. ISSN 2296-5262

Eisert, A., Scheffler, M., Frank, R., Gogl, L., Scheel, A., Merkelbach-Bruse, S., Michels, S., Fischer, R., Buttner, R. and Wolf, J. (2015). Clinical and genetic presentation of high-level cMET-amplified Non-small cell lung cancer (NSCLC) with adenocarcinoma histology. Eur. J. Cancer, 51. S. S646 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

Engelmann, E., Scheel, A., Buhr, M., Kruis, W. and Schlesinger, A. (2020). Cough meets Colic - a rare Cause of a progressive Cough - a Case Report. Pneumologie, 74. S. S137 - 2. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790

Fischer, R. N., Abdulla, D., Michels, S., Nogova, L., Brandes, V, Scheffler, M., Schaeffer, S., Scheel, A., Thurat, M., Vehreschild, M., Thomas, R., von Bergwelt-Baildon, M., Buettner, R. and Wolf, J. (2016). Bioluma: Biomarkers for nivolumab and evaluation of nivolumab plus ipilimumab in lung cancer - A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response to immune checkpoint inhibition. Oncol. Res. Treat., 39. S. 92 - 94. BASEL: KARGER. ISSN 2296-5262

Fischer, R. N., George, J., Schaefer, S., Scheel, A., Schloesser, H., Vehreschild, M., von Bergwelt-Baildon, M., Nogova, L., Abdulla, D. S. Y., Michels, S., Riedel, R., Scheffler, M., Brossart, P., Engel-Riedel, W., Griesinger, F., Grohe, C., Kambartel, K., Kern, J., Kopp, H-G, Neukirchen, J., Overbeck, T. R., Panse, J., Sebastian, M., Serke, M., Wiewrodt, R., Buettner, R., Thomas, R. and Wolf, J. (2018). BIOLUMA: Biomarkers for nivolumab and evaluation of nivolumab plus ipilimumab in lung cancer. Oncol. Res. Treat., 41. S. 270 - 272. BASEL: KARGER. ISSN 2296-5262

Fischer, R. N., George, J., Scheel, A., Schloesser, H., Brossart, P., Engel-Riedel, W., Griesinger, F., Grohe, C., Kern, J. K., Panse, J., Sebastian, M., Serke, M., Wiewrodt, R., Michels, S., Nogova, L., Riedel, R., Weber, J-P., Buettner, R., Thomas, R. and Wolf, J. (2022). BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response - results from the NSCLC cohort. Ann. Oncol., 33 (7). S. S1025 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Fries, J., Buchner, D., Chang, D. -H., Scheel, A., Buettner, R., Hoelscher, A. and Drebber, U. (2016). Phlebosclerosis of submucosal veins leading to ischemic necrosis of the large bowel: The first reported European case of so-called phlebosclerotic colitis with unusual features. Virchows Arch., 469. S. S264 - 1. NEW YORK: SPRINGER. ISSN 1432-2307

Knittel, G., Liedgens, P., Korovkina, D., Seeger, J. M., Al-Baldawi, Y., Vlantis, K., Fritz, C., Schaefer, S. C., Klatt, A., Scheel, A., Al-Maarri, M., Bezhanova, S., Montesinos-Rongen, M., Wolz, O. O., Reimann, M., Lohneis, P., Weber, A. N., Wunderlich, F. T., Pasparakis, M. ORCID: 0000-0002-9870-0966, Buettner, R., Persigehl, T., Schmitt, C. A., Odenthal, M., Frenzel, L. P., Kashkar, H. and Reinhardt, H. C. (2016). B CELL-SPECIFIC CONDITIONAL EXPRESSION OF MYD88P.L252P LEADS TO THE DEVELOPMENT OF DIFFUSE LARGE B CELL LYMPHOMA IN MICE. Haematologica, 101. S. 179 - 181. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Kostenko, A., Kron, F., Scheffler, M., Michels, S., Sueptitz, J., Fischer, R., Merkelbach-Bruse, S., Scheel, A., De-Mary, P., Glossmann, J. -P, Buettner, R. and Wolf, J. (2015). Comprehensive multiplex genotyping in lung cancer: challenges and opportunities of interdisciplinary networking using the example of the Network Genomic Medicine. Oncol. Res. Treat., 38. S. 268 - 269. BASEL: KARGER. ISSN 2296-5262

Kostenko, A., Kron, F., Scheffler, M., Michels, S., Sueptitz, J., Fischer, R., Merkelbach-Bruse, S., Scheel, A., De-Mary, P., Glossmann, J. P., Buettner, R. and Wolf, J. (2015). Broad implementation of next generation sequencing based lung cancer genotyping in clinical routine within a nationwide health care provider network in Germany. Eur. J. Cancer, 51. S. S597 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

Kostenko, A., Michels, S., Kron, F., Brandes, V, Fischer, R., Nogova, L., Scheffler, M., Fassunke, J., Merkelbach-Bruse, S., Scheel, A., Ueckeroth, F., Sueptitz, J., Gerigk, M., Heydt, C., Glossmann, J. -P, Buettner, R. and Wolf, J. (2016). Improved overall survival following implementation of next generation sequencing in routine diagnostics of advanced lung cancer in Germany: results of the Network Genomic Medicine. Oncol. Res. Treat., 39. S. 305 - 307. BASEL: KARGER. ISSN 2296-5262

Kuczkowski, A., Oermann, M., Zeglam, S., Scheel, A., Buhr, M. and Schlesinger, A. (2020). Rheumatism in Pneumology - A retrospective Analysis of 212 suspected ILD-Cases. Pneumologie, 74. S. S62 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790

Michels, S., Fischer, R., Heydt, C., Ihle, M., Scheffler, M., Scheel, A., Ortiz-Cuaran, S., Nogova, L., Brandes, V, Sos, M., Buettner, R., Merkelbach-Bruse, S. and Wolf, J. (2016). Mechanisms of primary and acquired resistance to 3rd generation EGFR TKI treatment in EGFR mutated lung adenocarcinoma. Oncol. Res. Treat., 39. S. 252 - 254. BASEL: KARGER. ISSN 2296-5262

Weber, J. -P., Fischer, R. N., George, J., Scheel, A., Westphal, T., Koleczko, S., Nogova, L., Riedel, R., Michels, S., Scheffler, M., Abdullah, D. S. Y., Sueptitz, J., Keser, E., Merkelbach-Bruse, S., Pinto, A., Buettner, R., Thomas, R. and Wolf, J. (2020). Small Cell Lung Cancer - Filling the gap between science and patients. Oncol. Res. Treat., 43 (SUPPL 4). S. 154 - 155. BASEL: KARGER. ISSN 2296-5262